Joel M. Rothman is the Chief Devel. Officer at Equillium Inc.
Mr Rothman is 52, he's been the Chief Devel. Officer of Equillium Inc since . There are 6 older and 10 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.
Joel's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA, CA, 92037.
Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski a Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Equillium Inc executives and other stock owners filed with the SEC include: